LITS.US Lite Strategy, Inc.

Healthcare Biotechnology USA Stocks
0.8467 USD
Close of Nov 15, 2026
0.6900 2.00
Market cap
USD 25.3M
P/E
-
P/B
0.44x
ROE
113.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is LITS.US undervalued?

Graham number

The Graham number of Lite Strategy, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lite Strategy, Inc. fundamental analysis

No fundamental analysis for Lite Strategy, Inc. yet.

Lite Strategy, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lite Strategy, Inc.

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Full company profile